Alken P - Search Results

1

Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides.

Bolenz C, Becker A, Trojan L, Schaaf A, Cao Y, Weiss C, Alken P, Michel MS. Bolenz C, et al. Among authors: alken p. Urol Oncol. 2007 Nov-Dec;25(6):476-82. doi: 10.1016/j.urolonc.2007.01.017. Urol Oncol. 2007. PMID: 18047955

2

Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides.

Schaaf A, Sagi S, Langbein S, Trojan L, Alken P, Michel MS. Schaaf A, et al. Among authors: alken p. Urol Oncol. 2004 May-Jun;22(3):188-92. doi: 10.1016/j.urolonc.2004.01.010. Urol Oncol. 2004. PMID: 15271313

3

Impact of holmium:YAG and neodymium:YAG lasers on the efficacy of DNA delivery in transitional cell carcinoma.

Knoll T, Trojan L, Langbein S, Sagi S, Alken P, Michel MS. Knoll T, et al. Among authors: alken p. Lasers Med Sci. 2004;19(1):33-6. doi: 10.1007/s10103-004-0299-5. Epub 2004 Jun 23. Lasers Med Sci. 2004. PMID: 15278722

4

Intravesical mitomycin C for superficial transitional cell carcinoma.

Bolenz C, Cao Y, Arancibia MF, Trojan L, Alken P, Michel MS. Bolenz C, et al. Among authors: alken p. Expert Rev Anticancer Ther. 2006 Aug;6(8):1273-82. doi: 10.1586/14737140.6.8.1273. Expert Rev Anticancer Ther. 2006. PMID: 16925493 Review.

5

Newly developed mini-endoscope for diagnosis and follow-up of orthotopic bladder transitional-cell carcinoma in vivo.

Bolenz C, Wenzel M, Cao Y, Trojan L, Häcker A, Arancibia MF, Alken P, Michel MS. Bolenz C, et al. Among authors: alken p. J Endourol. 2007 Jul;21(7):789-94. doi: 10.1089/end.2006.0355. J Endourol. 2007. PMID: 17705773

6

Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder.

Fernández MI, Bolenz C, Trojan L, Steidler A, Weiss C, Alken P, Grobholz R, Michel MS. Fernández MI, et al. Among authors: alken p. Eur Urol. 2008 Mar;53(3):571-8. doi: 10.1016/j.eururo.2007.08.030. Epub 2007 Aug 24. Eur Urol. 2008. PMID: 17804149

7

Topical chemotherapy in human urothelial carcinoma explants: a novel translational tool for preclinical evaluation of experimental intravesical therapies.

Bolenz C, Ikinger EM, Ströbel P, Trojan L, Steidler A, Fernández MI, Honeck P, Gabriel U, Weiss C, Grobholz R, Alken P, Michel MS. Bolenz C, et al. Among authors: alken p. Eur Urol. 2009 Sep;56(3):504-11. doi: 10.1016/j.eururo.2008.07.042. Epub 2008 Jul 30. Eur Urol. 2009. PMID: 18691807

8

Cellular uptake and ex vivo urothelial penetration by oligodeoxynucleotides for optimizing treatment of transitional cell carcinoma.

Bolenz C, Trojan L, Gabriel U, Honeck P, Wendt-Nordahl G, Schaaf A, Alken P, Michel MS. Bolenz C, et al. Among authors: alken p. Anal Quant Cytol Histol. 2008 Oct;30(5):265-73. Anal Quant Cytol Histol. 2008. PMID: 18980158

9

Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer.

Bode C, Trojan L, Weiss C, Kraenzlin B, Michaelis U, Teifel M, Alken P, Michel MS. Bode C, et al. Among authors: alken p. Oncol Rep. 2009 Aug;22(2):321-6. Oncol Rep. 2009. PMID: 19578772

10

Micelle delivery of doxorubicin increases cytotoxicity to prostate carcinoma cells.

McNealy TL, Trojan L, Knoll T, Alken P, Michel MS. McNealy TL, et al. Among authors: alken p. Urol Res. 2004 Aug;32(4):255-60. doi: 10.1007/s00240-003-0321-6. Epub 2004 Jan 9. Urol Res. 2004. PMID: 14714155

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

386 results

Search Page

Filters